Sai Mirra Innopharm

What Sai Mirra Innopharm does

Sai Mirra Innopharm Private Limited is a Chennai-based, fully integrated pharmaceutical manufacturer founded in April 2001, operating a multi-dosage form facility in the SIDCO Industrial Estate at Ambattur that produces tablets, soft-gel and hard-gel capsules, oral liquids, and oral powder sachets. The company was acquired by a new professional management team in September 2012, which repositioned it toward regulatory-grade manufacturing for global markets; its product portfolio spans antiretrovirals, cardiovascular, anti-diabetics, gastrointestinal, anti-infectives, antimalarials, gynecology, anti-allergics, respiratory, urology, neurology, and nutraceutical formulations. The company maintains a Drug Testing Laboratory approved under Form 37 with HPLC and microbiological testing capabilities, and operates Formulation R&D with two decades of internal expertise in product development, process validation, and lab-to-commercial scale-up.

The business runs three revenue streams. First, international exports to over 70 countries through direct B2B relationships with government health ministries, international pharmaceutical distributors, and institutional buyers, supported by accreditations including WHO GMP, PIC/S (cleared from Malaysia), and country-specific approvals from FDA Philippines, FDA Ghana, NAFDAC Nigeria, NDA Uganda, PPB Kenya, PMPB Malawi, Ivory Coast, DR Congo, and Kingdom of Cambodia. Second, domestic Indian marketing through the company's own divisions and the Delvin Formulations brand (merged in 2025), covering chronic care, gastro care, diabetes care, and primary care therapeutic segments. Third, contract manufacturing and CRO services drawing on integrated API, formulation, and bio-equivalence capabilities for other pharmaceutical clients. Pricing is not publicly disclosed and is negotiated per-contract or per-tender; pricing signals are absent.

The company is privately held (legal entity: SaiMirra Innopharm Private Limited, incorporated in India), with 11-50 employees and headquarters at Plot No. 288, 298 & 299, SIDCO Industrial Estate, Ambattur, Chennai - 600098. Board composition includes Mr. Jayaseelan (Founder and Director), Mr. Samy Shanmugam (Board of Director, MS, R.Ph, with prior roles at Ivax, Kali Labs, Par Pharmaceuticals, and Novel Labs), Yuvaraj J (Executive Director), Bharath J J (Chief Experience Officer), Thanigainathan T (Director - Plant Operations), and Sugirtha J J (Key Management Team Member). In April 2025, the company raised ₹160 crore (~US$18.8M) from Piramal Alternatives for expansion, brand acquisitions, and R&D.

Name

Sai Mirra Innopharm

Legal name

SaiMirra Innopharm Private Limited

Website

https://saimirra.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

Sai Mirra Innopharm is a Chennai-based, fully integrated pharmaceutical manufacturer producing generic formulations in tablets, capsules, oral liquids, and sachets for export to 70+ countries and for domestic Indian sale via its Delvin Formulations brand.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Flavoring Syrup and Concentrate Manufacturing (31193), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833), Beverages (2080)

akta.pro primary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

akta.pro secondary industries

Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Concentrate/Syrup & Flavor Base Contract Manufacturing (AFAFAIAI)

Keywords

• Generic pharmaceutical manufacturing
• Pharmaceutical formulation exports
• Contract manufacturing services
• Antiretroviral drug production
• Multi-dosage form manufacturing

Headquarters

HQ city

Chennai

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. International Exports: SaiMirra exports a diverse portfolio of specialty and generic drug products to over 70 countries, covering antiretrovirals, cardiovascular, diabetes, gastrointestinal, anti-infectives, antimalarials, gynecology, anti-allergic, respiratory, urology, neurology, and nutraceutical products. Revenue is generated through direct B2B export sales to international pharmaceutical distributors and tender buyers, with regulatory-compliant products registered in destination markets.
2. Domestic Marketing: Marketing and sale of pharmaceutical formulations within India through the company's own domestic marketing divisions and the acquired brand Delvin Formulations. Covers chronic care, gastro care, diabetes care, and primary care segments. Revenue is generated through sales to Indian pharmaceutical distributors and healthcare networks.
3. Contract Manufacturing / CRO Services: Provides contract manufacturing and Contract Research Organization (CRO) services drawing on integrated API, formulation, and bio-equivalence capabilities. R&D services include tech transfers, product/process know-how, and new formulation development for clients.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Sai Mirra Innopharm manufactures and supplies generic and specialty pharmaceutical formulations including tablets, capsules (soft-gel and hard-gel), liquid dosage forms, and oral sachets. The company operates a fully integrated pharmaceutical business covering API sourcing, formulation R&D, manufacturing, CRO, and bio-equivalence services, exporting formulations to over 70 countries and serving the Indian domestic market through its own marketing divisions and the Delvin Formulations brand.

Product overview

SaiMirra Innopharm is a fully integrated pharmaceutical company offering a comprehensive portfolio of generic and specialty drug products. The company operates two main product lines: International Exports (formulations exported to 70+ countries covering antivirals, cardiovascular, anti-diabetics, gastrointestinal, anti-infectives, and more) and Domestic Marketing (offered through acquired brand Delvin Formulations with Chronic Care, Gastro Care, Diabetes Care, and Prima sub-brands). The company manufactures various dosage forms including tablets, capsules (soft/hard), liquid formulations, oral sachets, and soft-gel capsules. In-house Formulation R&D services support product development and tech transfers.

Differentiator

Problem solved

Functional benefit

Brands

• Chronic: Chronic care formulations for domestic market
• Gastro
• Diabetes
• Prima

Products and services

• International Export Formulations

Quantifiable outcome

• Exports formulations to over 70 countries globally
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Delvin FormulationscoreStrategic or Co-development PartnerDelvin Formulations has merged into SaiMirra Innopharm, with SaiMirra taking on full responsibility for Delvin's operations and continuing its legacy of innovation and excellence. Delvin Formulations brought decades of experience and strong foundations in innovation, quality, and customer satisfaction, with recognized dedication to healthcare professionals and patients. The merger enables SaiMirra to enhance patient care, expand product innovation, and strengthen its domestic market position through Delvin's chronic care, gastro care, diabetes care, and primary care brand portfolio.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Aurobindo Pharma: Large Indian generic manufacturer with extensive ARV and emerging-market export footprint, including WHO GMP/PIC/S facilities and global formulations manufacturing. Direct overlap in antiretroviral and chronic-care generics exported to Africa and Southeast Asia, though at substantially greater scale and with broader dosage-form coverage.
• Cipla: One of India's largest generic pharmaceutical manufacturers with deep ARV portfolio and dominant presence in African and emerging markets. Comparable in target customer base (global health procurement, African national tenders) and core ARV/specialty-generic product mix, though operating with far larger scale, multi-site facilities, and broader therapeutic breadth.
• Lupin Pharmaceuticals: Major Indian generic manufacturer with global manufacturing footprint and significant presence in chronic-care, anti-infectives, and women's health categories. Overlaps with Sai Mirra on therapeutic portfolio breadth, multi-dosage manufacturing, and emerging-market exports, though at substantially larger scale with US FDA-approved facilities.

Direct peers

• Emcure Pharmaceuticals: India-based mid-sized generic manufacturer with significant emerging-market exports and integrated formulation manufacturing across multiple dosage forms. Closely comparable in scale, target markets (Africa, Asia, Latin America), product categories (ARVs, chronic care, women's health), and integrated R&D-to-commercial model, making it the most direct peer for Sai Mirra.
• Macleods Pharmaceuticals: Privately held Indian generic manufacturer with a leading ARV portfolio and strong presence in African and Asian tender markets. Highly comparable on therapeutic focus (ARVs, anti-infectives, chronic care), WHO-GMP manufacturing footprint, and emerging-market GTM, although Macleods operates at significantly larger scale.
• Strides Pharma Science: Indian generic manufacturer specializing in multiple dosage forms (tablets, capsules, soft gels, liquids) with strong emerging-market export business. Direct overlap in multi-dosage manufacturing capabilities, regulated-market accreditations, and Africa/Asia commercial footprint, with a similar pivot toward chronic care and specialty generics.
• Hetero Labs: Privately held Indian pharmaceutical company and one of the world's largest producers of generic ARVs, with integrated API-to-formulations manufacturing and a dominant role in Global Fund/PEPFAR supply. Comparable in ARV focus, integrated value chain, and emerging-market GTM, with deeper scale and broader global health partnerships.
• Granules India: Indian manufacturer focused on high-volume oral solid dosage forms with significant export footprint to regulated and emerging markets. Direct overlap in multi-dosage tablet/capsule manufacturing, export-led GTM, and integration into global generics supply chains, with comparable regulatory accreditations (US FDA, WHO GMP).
• Ajanta Pharma: Indian specialty generic manufacturer with strong emerging-market (Africa, Asia) export franchise and branded domestic presence. Comparable on target geographies, therapeutic focus (chronic care, anti-infectives), and integrated formulation manufacturing model, with a similar scale band to Sai Mirra.

Regional players

• Laurus Labs: Indian pharmaceutical company with integrated API manufacturing and a growing generics/formulations business serving emerging markets and developed geographies. Comparable in vertically integrated model (API + formulations) and emerging-market export focus, though more API-centric than Sai Mirra and exposed to US generics as well.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/sai-mirra-pharmaceuticals-private-limited

Compliance15 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sai Mirra Innopharm